Tuesday, May 19, 2026
← Back to archivePolicy
Policy•Fierce Pharma•May 19, 2026
AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too
background ▾
- •Baxdrostat FDA approval marks a novel mechanism (aldosterone synthase inhibitor) entering the hypertension market, addressing a significant unmet need in resistant hypertension management
- •This approval is a material revenue driver for AstraZeneca's $80B revenue goal by 2030, reflecting successful execution of the CinCor acquisition strategy
- •Monitor peak sales projections for baxdrostat and the competitive landscape as other ASI programs advance; clarify what the Fasenra labeling advantage entails
AstraZenecaCinCor PharmabaxdrostatFasenra
→ Read original articlePolicy•Fierce Biotech•May 18, 2026
Nominations now open for Fierce Biotech's 2026 Fierce 15
background ▾
- •This is a call for nominations to an industry awards program with no regulatory, clinical, or market-moving implications
Policy•KFF•May 19, 2026
What We Know So Far About 2026 ACA Marketplace Enrollment, Premiums, and Deductibles
background ▾
- •ACA Marketplace enrollment is projected to decline by 17-26% in 2026 (3.8-5.8 million people), the sharpest contraction since marketplace inception, driven by expiration of enhanced premium tax credits that had expanded subsidies through 2025
- •Average marketplace deductibles increased by approximately $1,000 per person in 2026, with enrollees shifting toward higher-deductible plans, signaling reduced out-of-pocket utilization capacity and potential downstream impacts on drug adherence and utilization
- •Effectuated enrollment (premium-paying members) will be materially lower than open enrollment sign-ups due to mid-year attrition, with only ~86% of January 2026 enrollees paying first-month premiums; state-based exchanges with robust subsidy programs and outreach retain higher shares than federally-facilitated exchanges
Policy•KFF•May 19, 2026
AI: As Much Peril As Promise?
background ▾
- •AI's success in healthcare may depend not on perfection but on exceeding current system performance, shifting physician roles from diagnosticians to curators of AI-generated information.
- •Key risks include AI's fundamental limitation in broad clinical judgment—the core requirement of medical practice—alongside technical issues like hallucinations and bias that could harm patients.
- •The trajectory of AI adoption will critically define future medicine and the physician-patient relationship, requiring careful consideration beyond technical capability alone.
Policy•Fierce Pharma•May 19, 2026
Supreme Court declines to hear IRA challenges from Novo, AZ and more
background ▾
- •The Supreme Court's refusal to hear IRA challenges eliminates the final major legal pathway for pharmaceutical companies to block or modify the law's drug pricing provisions.
- •This follows multiple prior court defeats for the industry, indicating consistent judicial deference to Congress on pharmaceutical pricing policy.
- •The industry must now focus on operational compliance and commercial strategies within the IRA framework rather than pursuing further litigation.
Novo NordiskAstraZeneca
→ Read original articleMarket Access
Market Access•Fierce Pharma•May 19, 2026
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
background ▾
- •Enhertu secured two new early breast cancer FDA approvals, substantially expanding its addressable market beyond metastatic disease and strengthening its position as a blockbuster asset
- •Approval arrived ~2 months ahead of expectations, signaling strong regulatory momentum and de-risking the label expansion strategy
- •Undisclosed conditions or limitations attached to the adjuvant approval may constrain real-world adoption and payer reimbursement in early breast cancer
Daiichi SankyoAstraZenecaEnhertutrastuzumab deruxtecan
→ Read original articleMarket Access•KFF•May 19, 2026
The Average Marketplace Deductible Grew by About $1,000 Per Person in 2026, With More Enrollees Shifting to Higher-Deductible Plans as Enhanced Tax Credits Expired
background ▾
- •Average ACA Marketplace deductible increased $1,000+ (37%) in 2026 as enhanced tax credits expired, with enrollment projected to decline 17-26% year-over-year—the steepest single-year drop since ACA inception
- •Bronze plan enrollment jumped from 30% to 40% of total selections while silver plan enrollment hit historic lows (43% vs. 57%), indicating patients are prioritizing lower premiums over lower cost-sharing despite higher deductibles
- •Middle-income individuals (above 400% of federal poverty level) now represent 48% of plan selection declines—a 'subsidy cliff' effect that will likely impact medication adherence, specialty drug uptake, and overall pharmaceutical demand in 2026
Market Access•Fierce Pharma•May 19, 2026
Novartis terminates plant contract with Chinese CDMO Porton, threatens $64M in legal claims
background ▾
- •Novartis terminated a manufacturing partnership with Chinese CDMO Porton and is pursuing $64M in legal claims due to regulatory failures
- •The action reflects growing tensions between major pharma and Chinese contract manufacturers over quality and compliance standards
NovartisPorton Pharma Solutions
→ Read original articleMarket Access•Fierce Pharma•May 19, 2026
Bristol Myers looks at Houston for potential $1B manufacturing plant
background ▾
- •Bristol Myers Squibb is planning a ~$1B domestic manufacturing investment, indicating strategic commitment to U.S. production capacity expansion.
Bristol Myers Squibb
→ Read original articleMarket Access•Fierce Pharma•May 19, 2026
How medical affairs drives real impact at launch
background ▾
- •Medical affairs teams should prioritize proactive evidence generation and cross-functional coordination to drive launch success
Clinical Trials
Clinical Trials•Fierce Biotech•May 18, 2026
BioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal
background ▾
- •BMN 401 achieved biomarker efficacy (plasma PPi elevation) but failed clinically relevant skeletal healing endpoint, creating a critical disconnect between mechanism of action and patient benefit
- •The $270 million Inozyme acquisition now appears to have limited return on investment with the lead asset showing insufficient clinical benefit for rare pediatric indication with high unmet need
- •BioMarin management has not ruled out further development, suggesting potential exploratory pathways or patient subgroup analyses—close monitoring needed for regulatory strategy and financial impact on near-term pipeline
BioMarin PharmaceuticalInozymeRocheBMN 401INZ-701Palynziq
→ Read original articleClinical Trials•Fierce Biotech•May 18, 2026
Sanofi and Wave post AATD updates in race to end genetic disease’s 40-year new treatment drought
background ▾
- •Efdoralprin alfa achieved clinically meaningful AAT levels (24.1 μM three-weekly) that sustain normal-range protection, addressing the long-standing treatment goal in a 40-year innovation drought for AATD
- •The recombinant protein's superior durability versus donor-sourced Zemaira enables less-frequent dosing while reducing exacerbation frequency, suggesting improved clinical outcomes beyond biomarker replacement
- •Wave's RNA editing approach (WVE-006) represents a potential paradigm shift from infusion-based replacement to self-administered monthly dosing with endogenous AAT production—monitor phase 2 progression and comparative efficacy data
SanofiWave Life SciencesCSLefdoralprin alfaZemairaWVE-006
→ Read original articleClinical Trials•Fierce Pharma•May 19, 2026
Merck, Kelun score with sac-TMT in endometrial cancer trial
background ▾
- •Sacituzumab tirumotecan met primary endpoints in a phase 3 endometrial cancer trial, supporting a new indication filing
- •The drug already has four China approvals, indicating established regulatory credibility and manufacturing capability for expansion
- •Success in endometrial cancer broadens sac-TMT's addressable market and validates the TROP2-ADC mechanism across multiple solid tumors
MerckKelun-Biotechsacituzumab tirumotecansac-TMT
→ Read original articleClinical Trials•Fierce Biotech•May 18, 2026
Vincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators
background ▾
- •VCT220 demonstrated 12.4% weight loss over 52 weeks with favorable tolerability profile (1.8% discontinuation), comparable to Lilly's orforglipron but lower than Novo Nordisk's Wegovy, creating a competitive mid-tier option in the crowded GLP-1 space.
- •Vincentage is pursuing imminent regulatory submission in China while Corxel advances the drug in the U.S. via Phase 2 data expected later this year, setting up a dual-market development strategy for an oral non-peptide small-molecule GLP-1.
- •Watch for Chinese regulatory approval timeline, Corxel's U.S. Phase 2 readout (expected H2 2025), and whether VCT220's convenience positioning (once-daily dosing, no refrigeration, short titration) drives differentiation despite modest efficacy vs. category leaders.
Vincentage PharmaCorxel PharmaceuticalsEli LillyVCT220orforglipronWegovy
→ Read original articleClinical Trials•STAT News•May 18, 2026
With no approved vaccine for Ebola outbreak, experts weigh testing a long shot
background ▾
- •Ervebo, already approved for Zaire ebolavirus, may offer cross-protection against Bundibugyo ebolavirus based solely on a small 2011 macaque study showing improved survival—an unusually weak evidence base for potential deployment in a large, active outbreak.
- •WHO's R&D Blueprint group is meeting Tuesday to formally discuss whether Ervebo should be tested in the outbreak, with final authority resting with DRC and Uganda authorities; key obstacles include low community trust in conflict zones and fundamental uncertainty about human efficacy.
- •This outbreak represents a rare scenario where regulatory and clinical uncertainty may force a decision to deploy an approved drug off-label for a related but distinct pathogen with minimal supporting data, setting precedent for future cross-species viral emergencies.
MerckErvebo
→ Read original article